The results showed a dose-dependent reduction in ZO-1 expression and increase in IL-1β (Figure 5F), suggesting that DEFA5 may play important roles in the compromise of intestinal barrier function and the development of intestinal inflammation in AD. Here, DEFA5 is linked to Alzheimer disease.